A recent randomized controlled trial published in Scientific Reports demonstrated beneficial effects on neurocognitive functions and symptoms when using a specific hyperbaric oxygen therapy (HBOT) protocol among patients with long COVID. Coauthor Amir Hadanny, MD, PhD, and colleagues, assessed the impact of HBOT in 73 post-COVID-19 patients for at least 3 months. In a recent interview with NeurologyLive®, Hadanny, a neurosurgeon and the chief medical research officer and head of research at Aviv Clinics, discussed the challenges that researchers face in conducting long-term evaluations of COVID treatments, and how they are addressing these issues.
View More: www.neurologylive.com/authors...
View More Alzheimer Content: www.neurologylive.com/clinica...